Up next

Autoplay

David Walling, PhD: Aripiprazole Lauroxil NanoCrystal Dispersion for Schizophrenia

1 Views • 08/17/25
Share
Side Effects
Side Effects
Subscribers
0

David Walling, PhD, the CEO of the Collaborative Neuroscience Network, sat down with MD Magazine at the American Psychiatric Associations’ annual meeting in New York City to discuss the results from a pharmacokinetic and safety study that evaluated aripiprazole lauroxil (Aristada, Alkermes) NanoCrystal Dispersion, a novel, investigational product designed for initiation onto the therapy. He talked about how, importantly, the new delivery allows for physicians to improve treatment adherence for patients with schizophrenia, who normally struggle greatly with keeping the medications they require in their systems.

Show more
0 Comments sort Sort By

Up next

Autoplay